Business Context and Reporting Period
Company: Dogwood Therapeutics, Inc. (formerly Virios Therapeutics, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: A pre-revenue, development-stage biopharmaceutical company focused on treating pain and peripheral neuropathy associated with cancer. Key pipeline assets include Halneuron® (Phase 2b for chemotherapy-induced neuropathic pain) and SP16 (licensed in Q3 2025 for Phase 1 development). The company operates as a single segment and is classified as an emerging growth company and smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 | Balance Sheet (Sept 30, 2025) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(15,744,616) | $(30,476,921) | N/A |
| Net Loss Attributable to Common Stockholders | $(15,744,616) | $(31,733,583) | N/A |
| Loss Per Share (Basic & Diluted) | $(8.20) | $(18.02) | N/A |
| Operating Expenses | $15,809,125 | $24,162,166 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $10,126,710 |
| Total Assets | N/A | N/A | $91,992,613 |
| Total Liabilities | N/A | N/A | $14,607,504 |
| Stockholders' Equity | N/A | N/A | $7,258,152 |
| Accumulated Deficit | N/A | N/A | $(104,295,867) |
Cash Flow (Nine Months Ended Sept 30, 2025):
- Net cash used in operating activities: $(11,981,464)
- Net cash provided by financing activities: $7,252,245
- Net decrease in cash: $(4,729,219)
Material Changes vs. Prior Period
- Revenue: Remained at $0, consistent with pre-revenue status.
- Operating Expenses: Increased significantly to $15.8 million for the quarter (from $2.3 million in Q3 2024) and $24.2 million for the nine months (from $4.7 million in the prior year period).
- Research & Development (R&D): Rose to $14.5 million for the quarter, driven primarily by a $12.0 million expense for acquired In-Process Research and Development (IPR&D) related to the SP16 license agreement with Serpin Pharma. Remaining increases were due to the HALT-CINP-203 clinical trial.
- General & Administrative (G&A): Decreased to $1.3 million for the quarter (from $1.8 million) due to lower legal and professional fees, though it increased year-to-date due to Combination-related costs.
- Other Income/Expense: Included a non-cash loss on debt conversion of $6.1 million for the nine months ended September 30, 2025, related to the exchange of a related-party loan for Series A-1 Preferred Stock.
- Liquidity: Cash balance decreased from $14.8 million at year-end 2024 to $10.1 million at September 30, 2025.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Warning
Management has expressed substantial doubt about the Company's ability to continue as a going concern for 12 months from the issuance date. Cash on hand ($10.1 million) is projected to fund operations only through the first quarter of 2026. Additional financing (equity, debt, or collaborations) will be required to fund ongoing clinical trials and operations beyond that date.
Key Developments and Unusual Items
- Debt Conversion: In March 2025, a $19.5 million related-party loan (plus accrued interest) was converted into Series A-1 Non-Voting Convertible Preferred Stock, resulting in a $6.1 million non-cash loss on debt extinguishment.
- SP16 License Agreement: In September 2025, the Company entered an exclusive license for SP16, issuing common stock and Series A-2 Preferred Stock valued at approximately $12.0 million, which was expensed immediately as acquired IPR&D.
- Equity Financing: Completed a registered direct offering in March 2025, raising net proceeds of approximately $4.25 million.
- Preferred Stock Waivers: In September 2025, holders waived cash settlement rights for certain Series A Preferred Stock, resulting in the reclassification of approximately $5.5 million from temporary equity to permanent equity.
Outlook
The HALT-CINP-203 Phase 2b trial for Halneuron® is ongoing, with an interim analysis planned for Q4 2025. The Company expects to release top-line data in the second half of 2026. SP16 is expected to enter Phase 1 development in the first half of 2026, funded by an NCI grant.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $10.1 million cash balance to fund operations through Q1 2026 and the timeline for securing additional capital.
- Dilution Risk: Assess the impact of outstanding convertible preferred stock (Series A, A-1, and A-2) and options on future common share count upon conversion.
- Clinical Milestones: Monitor the Q4 2025 interim analysis of the HALT-CINP-203 trial, as a futility determination could materially impact the business strategy.
- Going Concern Status: Review management's specific plans for raising capital and the terms of any potential future financings.
- Related Party Transactions: Review the terms of the debt conversion and the ongoing relationship with Conjoint Inc. (affiliate of CKLS).